Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
X-TROZINE L.A. vs COVERA-HS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
X-TROZINE L. A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
Verapamil hydrochloride is a phenylalkylamine calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, thereby reducing afterload and myocardial contractility. In the heart, it slows atrioventricular conduction and prolongs the effective refractory period; in vascular smooth muscle, it causes vasodilation, reducing peripheral vascular resistance.
Hypertension (extended-release formulation),Off-label: Management of opioid withdrawal symptoms
Hypertension,Angina pectoris including chronic stable angina, vasospastic (Prinzmetal's) angina, and unstable angina,Supraventricular tachyarrhythmias including atrial fibrillation/flutter and paroxysmal supraventricular tachycardia
250 mg orally once daily. May be increased to 500 mg once daily if needed.
180 mg orally once daily at bedtime, extended-release tablet. Maximum dose 540 mg/day.
12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min).
Terminal elimination half-life is 6–17 hours for immediate-release; for Covera-HS (controlled-onset extended-release), the half-life is 10–20 hours, allowing once-daily bedtime dosing to achieve peak effect in the morning.
Primarily hepatic via CYP3A4; metabolites include inactive glucuronides.
Primarily hepatic metabolism via cytochrome P450 enzymes, including CYP3A4, CYP2C8, and CYP1A2, with extensive first-pass effect. Major metabolites include norverapamil (active) and various dealkylated and conjugated metabolites.
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Primarily hepatic metabolism (oxidation and glucuronidation) with renal excretion of inactive metabolites; approximately 80% of metabolites are excreted renally and 15% fecally.
95-98% bound to albumin and alpha-1-acid glycoprotein.
95–98% bound to plasma proteins, primarily to albumin.
0.8-1.2 L/kg, indicating extensive tissue distribution.
2.0–2.5 L/kg, indicating extensive tissue distribution.
Oral: 40-60% (due to first-pass metabolism); IM: 80-90%.
Oral: 70–86% due to first-pass metabolism.
Cr Cl 30-89 m L/min: 250 mg every 48 hours. Cr Cl <30 m L/min: 250 mg every 72 hours. Hemodialysis: 250 mg post-dialysis three times weekly.
GFR 30-80 m L/min: no adjustment; GFR <30 m L/min: start at 180 mg daily, titrate cautiously. Not dialyzable.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 250 mg once daily. Child-Pugh C: use is not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Children ≥2 years: 5 mg/kg orally once daily, maximum 250 mg. Adolescents: 250 mg once daily.
Safety and efficacy not established; no recommended dosing.
Initiate at 125 mg once daily; titrate cautiously. Monitor renal function and adjust per renal guidelines.
Start at 180 mg orally once daily; titrate slowly due to increased sensitivity and reduced clearance.
X-TROZINE L. A. carries a black box warning for severe hypotension and syncope, especially on initial dosing or dose escalation; risk of orthostatic hypotension is increased with concomitant use of diuretics or beta-blockers.
None
May cause bradycardia and heart block; caution in patients with pre-existing cardiac conduction abnormalities. Avoid abrupt discontinuation due to risk of rebound hypertension. Use with caution in patients with renal impairment (dose adjustment recommended). May cause drowsiness and impaired cognitive function.
May cause hypotension, especially in patients with ventricular dysfunction,Can precipitate heart failure or worsen pre-existing heart failure,Risk of bradycardia and heart block, especially in patients with sick sinus syndrome or pre-existing conduction defects,Caution in patients with hypertrophic cardiomyopathy due to risk of worsening obstruction and hypotension,Avoid abrupt withdrawal in patients with angina; may cause severe exacerbation,May increase serum levels of digoxin, cyclosporine, and other CYP3A4 substrates,Use with caution in patients with hepatic impairment due to reduced clearance,May cause symptomatic hypotension when administered with beta-blockers or other antihypertensives,Monitor for constipation, especially in elderly patients
Hypersensitivity to piperazine derivatives; severe bradycardia or sick sinus syndrome without pacemaker; concurrent use of MAO inhibitors; history of hepatic encephalopathy.
Severe left ventricular dysfunction (ejection fraction <30%),Hypotension (systolic blood pressure <90 mm Hg),Cardiogenic shock,Sick sinus syndrome (unless pacemaker in place),Second- or third-degree AV block (unless pacemaker in place),Atrial fibrillation/flutter with accessory bypass tract (e.g., Wolff-Parkinson-White syndrome),Known hypersensitivity to verapamil or any component of the formulation,Concurrent use of ivabradine
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase drug levels, raising risk of side effects. Take with or without food; if GI upset occurs, take with a small meal.
Avoid grapefruit and grapefruit juice; may increase verapamil serum concentrations. Limit alcohol intake; can potentiate hypotensive effects and increase risk of bradycardia. High-fat meals may delay absorption but do not significantly alter AUC; take consistently with food.
First trimester: Associated with increased risk of neural tube defects (NTDs) and oral clefts based on animal studies and limited human data; second and third trimester: Risk of fetal growth restriction and oligohydramnios due to potential effects on placental perfusion.
First trimester: No increased risk of major congenital malformations based on limited human data; animal studies show fetotoxicity at high doses. Second/third trimester: Associated with fetal hypotension, oligohydramnios, intrauterine growth restriction (IUGR), and hypocalcemia. May cause preterm delivery and neonatal renal impairment.
Excreted into breast milk; M/P ratio approximately 0.8. Avoid breastfeeding due to potential adverse effects on infant neurodevelopment and risk of hypotonia.
Verapamil (active ingredient) is excreted into human breast milk at low concentrations (M/P ratio ~0.6-0.8). Estimated infant dose is <0.1% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for hypotonia, bradycardia, and constipation.
Increased clearance due to expanded plasma volume and enhanced hepatic metabolism; dose may need to be increased by 30-50% in the second and third trimesters; monitor therapeutic drug levels.
No specific dose adjustments are routinely recommended; however, pharmacokinetic changes in pregnancy (increased plasma volume, increased renal clearance) may necessitate dose titration based on clinical response. Consider using lowest effective dose to minimize fetal hypotension and hypoperfusion.
X-TROZINE L. A. is a long-acting antihistamine used for allergic rhinitis and chronic urticaria. Its peak effect occurs 6-12 hours post-dose; avoid concurrent use with CNS depressants due to additive sedation. In elderly patients, reduce dose to prevent anticholinergic side effects like urinary retention and blurred vision. Monitor liver function in patients with hepatic impairment as metabolism is hepatic via CYP3A4.
Covera-HS (verapamil extended-release) is formulated for bedtime dosing to maximize blood pressure control during early morning surge. Avoid use in patients with pre-excited atrial fibrillation (Wolff-Parkinson-White syndrome) due to risk of ventricular fibrillation. Monitor for constipation, especially in elderly. Adjust dose in hepatic impairment; contraindicated in severe left ventricular dysfunction and hypotension.
Take exactly as prescribed, usually once daily; do not crush or chew the extended-release tablet.,May cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other sedatives to prevent increased drowsiness.,Notify your doctor if you experience vision changes, difficulty urinating, or rapid heartbeat.,Store at room temperature away from moisture and heat.
Take exactly as prescribed, usually once daily at bedtime, with food to minimize gastrointestinal irritation.,Swallow tablet whole; do not crush, chew, or break.,Do not discontinue abruptly; may cause rebound hypertension or angina.,Avoid grapefruit juice and alcohol; they can increase verapamil levels or enhance side effects.,Report symptoms such as slow heartbeat, dizziness, fainting, or swelling of ankles/feet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about X-TROZINE L.A. vs COVERA-HS, answered by our medical review team.
X-TROZINE L.A. is a Antihistamine that works by X-TROZINE L. A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.. COVERA-HS is a Calcium Channel Blocker that works by Verapamil hydrochloride is a phenylalkylamine calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, thereby reducing afterload and myocardial contractility. In the heart, it slows atrioventricular conduction and prolongs the effective refractory period; in vascular smooth muscle, it causes vasodilation, reducing peripheral vascular resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between X-TROZINE L.A. and COVERA-HS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of X-TROZINE L.A. is: 250 mg orally once daily. May be increased to 500 mg once daily if needed.. The standard adult dose of COVERA-HS is: 180 mg orally once daily at bedtime, extended-release tablet. Maximum dose 540 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between X-TROZINE L.A. and COVERA-HS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. X-TROZINE L.A. is classified as Category C. First trimester: Associated with increased risk of neural tube defects (NTDs) and oral clefts based on animal studies and limited human data; second and third trimester: Risk of fe. COVERA-HS is classified as Category C. First trimester: No increased risk of major congenital malformations based on limited human data; animal studies show fetotoxicity at high doses. Second/third trimester: Associated. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.